AJMC® in the Press, March 8, 2019

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

A study published in The American Journal of Managed Care® (AJMC®) was highlighted by Becker’s Hospital Review in its article on value-based contracts. The study, “Value-Based Arrangements May Be More Prevalent Than Assumed,” revealed that the majority of value-based arrangements are not publicly disclosed, and focusing solely on publicly known arrangements greatly underestimates their prevalence and potential impact.

America’s Health Insurance Plans’ Monday SmartBrief included a study published in The American Journal of Accountable Care®, “ACO Use of Case Mix Index to Comprehensively Evaluate Postacute Care Partners,” which described how one accountable care organization (ACO) created a risk-adjusted algorithm to evaluate current and potential candidates for skilled nursing facility (SNF) partnerships. The authors concluded that incorporating a risk-adjusted approach to ranking, then selecting, preferred SNF partners is paramount for the future of ACOs.

Articles from Journal Tribune and Central Maine included the AJMC®-published study “Simply Delivered Meals: A Tale of Collaboration.” The study found that offering a meal delivery service to patients in a community-based care transition program was associated with cost savings and a 38% lower 30-day hospital readmission rate.

An article from AJMC® was included in the National Pharmaceutical Council’s Monday CER Daily Newsfeed. The article, “Progressing From Identifying and Measuring to Reducing Low-Value Care Services,” covered a webinar from the University of Michigan’s Center for Value-Based Insurance Design that explained reducing the use of low-value care creates more headroom in the health system to improve care and spend money elsewhere. Wednesday’s newsfeed included AJMC®’s article “Carfilzomib Regimen Results in Longer Time to Next Treatment, Improved Survival in RRMM,” which covered a study demonstrating that a carfilzomib-based regimen resulted in longer time to next treatment and improved survival among patients with relapsed or refractory multiple myeloma.

OBR Oncology’s Thursday daily newsfeed included an article from AJMC®’s sister publication The Center for Biosimilars®. The article, “How Will Biosimilars Fare in the FDA Post Gottlieb and Christl?” covered the departures of FDA Commissioner Scott Gottlieb, MD, and Leah Cristl, PhD, previously the director of the Therapeutic Biologics and Biosimilars Staff in the Office of New Drugs, which could have an impact on the agency’s approach to biosimilars.